Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Glaucoma

Glaucoma

Subtypes of Glaucoma

Open-angle glaucoma 7 Normal-tension glaucoma 2 Primary Angle Closure Glaucoma 2 Neovascular glaucoma 1 Primary congenital glaucoma 1

26 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Glaucoma

157 trials tracked for Glaucoma: 68 in phase 3 or 4 and 7 with published results. The most-cited published study has 319 citations.

157Trials tracked
68Phase 3 & 4
0Recruiting
7With published results
Phase distribution
Phase 4 45 Phase 3 23 Phase 2 13 Phase 1 5 Other / NA 71
  1. Phase 4 Primary Tube Versus Trabeculectomy Study Completed · 319 cited
  2. Phase 3 Long-Term Safety of Latanoprostene Bunod Ophthalmic Solution 0.024% in Japanese Subjects With OAG or OHT Completed · 79 cited
  3. Phase 4 XEN-45 Gel Stent Versus Trabeculectomy in Glaucoma: Gold-Standard Pathway Study (GPS) Completed · 45 cited
  4. Phase 3 A Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients With Open-Angle Glaucoma or Ocular Hypertension Completed · 24 cited
  5. Phase 4 Glaucoma Biomarkers Completed · 17 cited
  6. Phase 3 Will the Use of Triesence During Glaucoma Surgery Provide Lower Eye Pressure and Improve the Results of the Surgery? Completed · 10 cited
Show 44 more trials
  1. Phase 4 How Similar Are Changes to the Surface of the Eye When Two Different Glaucoma Eye Drops Are Used? Completed · 9 cited
  2. Phase 4 Steroids After Laser Trabeculoplasty for Glaucoma Completed
  3. Phase 4 COSOPT-S® Treatment Versus Acetazolamide Before Trabeculectomy Completed
  4. Phase 4 Effect of Myocilin Genetic Variants on Intraocular Pressure and Pressure Variation in Sitting and Supine Positions Completed
  5. Phase 4 24-hr Intraocular Pressure Control With SIMBRINZA ® Completed
  6. Phase 4 Long-Term Safety of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension Completed
  7. Phase 4 Comparison of Combigan Two Times Daily (BID) Versus Simbrinza Three Times Daily (TID) Completed
  8. Phase 4 Additive Effect of Twice-daily Brinzolamide 1%/Brimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension Glaucoma Completed
  9. Phase 4 Use of Bevacizumab in Trabeculectomy Surgery Completed
  10. Phase 4 Rocklatan® Evaluation Completed
  11. Phase 4 Comparison of Visual Field Assessments Between Three Perimeters Completed
  12. Phase 4 Safety and Efficacy of Bimatoprost Compared With Latanoprost in Patients With Glaucoma or Ocular Hypertension Completed
  13. Phase 4 Effects of Travatan Z and Xalatan on Ocular Surface Health Completed
  14. Phase 4 Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on Brimonidine 0.2%/Timolol 0.5% Fixed Combination Therapy (COMBIGAN®) in Latin America Completed
  15. Phase 4 24-hour IOP-lowering Effect of 0.01% Bimatoprost Completed
  16. Phase 4 Safety, Efficacy Assessment of Geltim LP® 1 mg/g in Ocular Hypertensive or Glaucomatous Patients. Completed
  17. Phase 4 12-Month Stability of Diurnal IOP Control on Cosopt Completed
  18. Phase 4 The Effects of Xalatan, Travatan and Lumigan on Skin Pigmentation Near the Eye Completed
  19. Phase 4 An Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension Completed
  20. Phase 4 Effect of Age on Latanoprost 0.005% in Patients With Glaucoma Completed
  21. Phase 4 Efficacy and Tolerability of AZARGA® as Replacement Therapy in Patients on COMBIGAN® Therapy in Canada Completed
  22. Phase 4 Efficacy and Safety of Travoprost 0.004% Versus Tafluprost 0.0015% in Patients With Primary Open-angle Glaucoma or Ocular Hypertension Completed
  23. Phase 4 An Evaluation of the Fixed Combination Brimonidine Tartrate 0.2%/ Timolol Maleate 0.5% to Latanoprost 0.005% in Glaucoma or Ocular Hypertension Subjects Completed
  24. Phase 4 An Efficacy and Tolerability Study of TRAVATAN® Versus LUMIGAN® Completed
  25. Phase 4 Comparing Effects of Two Fixed Combinations Ophthalmic Solutions on Ocular Blood Flow Completed
  26. Phase 4 Circadian Ocular Perfusion Pressure and Ocular Blood Flow Completed
  27. Phase 4 Effect of Nitrous Oxide (N2O) on Intraocular Pressure in Healthy Volunteers Completed
  28. Phase 4 Safety and Efficacy of Adding AZARGA® Adjunctive to Prostaglandin Therapy Completed
  29. Phase 4 Safety and Efficacy of Changing to DuoTrav in Patients Uncontrolled on Timolol Completed
  30. Phase 4 Travatan Versus Timoptic in Treating Open-angle Glaucoma or Ocular Hypertension Completed
  31. Phase 4 A Comparison of Azopt Versus Placebo Added to Xalatan in Patients With Elevated Intraocular Pressure (IOP) on a Prostaglandin Completed
  32. Phase 4 A Phase IV Study of Travoprost + Brinzolamide to Treat Glaucoma or Ocular Hypertension Completed
  33. Phase 4 Pilot Study on the Use of Artificial Tears to Treat Dry Eye in Glaucoma Patients Completed
  34. Phase 4 Earlier Intraocular Pressure Control After Ahmed Glaucoma Valve Implantation for Glaucoma Completed
  35. Phase 4 AZARGA Transition Study in Taiwan for Patients With Uncontrolled Intraocular Pressure Completed
  36. Phase 4 A Comparison of Three Different Formulations of Prednisolone Acetate 1% Completed
  37. Phase 4 Assessment of Intraocular Pressure (IOP) Control in Subjects With Open-Angle Glaucoma or Ocular Hypertension Treated With Travoprost 0.004% (TRAVATAN® Z) or Bimatoprost 0.01% (LUMIGAN®) Completed
  38. Phase 4 A Safety and Efficacy Study of ALPHAGAN® P and LUMIGAN® in Subjects Previously Treated With Latanoprost for Glaucoma and Ocular Hypertension Completed
  39. Phase 4 Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension Completed
  40. Phase 4 Bimatoprost 0.03% Versus Travoprost 0.004% in Patients Currently on Latanoprost 0.005% Completed
  41. Phase 4 Comparing Safety and Efficacy of Combigan® and Lumigan® With Lumigan® Alone in Glaucoma or Ocular Hypertension Subjects Treated With Xalatan® Completed
  42. Phase 4 Comparing Efficacy and Safety of Combigan With Timolol Adjunctive to Xalatan in Glaucoma or Ocular Hypertension Subjects Completed
  43. Phase 3 Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension Completed
  44. Phase 3 Bioequivalence Study With Clinical Endpoint Comparing Brinzolamide 1% Ophthalmic Suspension to Azopt® 1% Ophthalmic Suspension In the Treatment of Chronic Open Angle Glaucoma or Ocular Hypertension in Both Eyes Completed

Showing the 50 most-cited and recently-updated of 157 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Polygenic risk score enrichment reduces sample size needs for coronary artery disease and inflammatory bowel disease trials
Genetics & Precision Medicine Cohort
Polygenic risk score enrichment reduces sample size needs for coronary artery disease and inflammatory bowel disease trials Smarter trial designs could cut study sizes by 60% for heart disease
This in silico observational cohort study used UK Biobank data to model trial designs enriched for polygenic risk.
Using genetic risk scores to pick high-risk volunteers could shrink trial sizes by 60% for heart disease and 78% for IBD, speeding up resear…
medRxiv Apr 23, 2026
Bleb Wall Thickness Not Associated With Secondary Interventions After Preserflo MicroShunt Implantation
Rheumatology Cohort
Bleb Wall Thickness Not Associated With Secondary Interventions After Preserflo MicroShunt Implantation Early bleb scans do not predict future surgery needs in glaucoma
This observational cohort study evaluated 23 open-angle glaucoma patients undergoing Preserflo MicroShunt implantation.
Early bleb measurements after glaucoma surgery do not predict which patients will need additional treatment procedures later.
Frontiers Apr 23, 2026
Preclinical study tests AI pipeline for glaucoma detection using Harvard dataset
Ophthalmology
Preclinical study tests AI pipeline for glaucoma detection using Harvard dataset New AI System Catches Glaucoma Cases That Other Tools Miss
This preclinical study evaluated a two-tier AI diagnostic pipeline for glaucoma using the Harvard Glaucoma Detection and Progression dataset…
This approach may help doctors spot glaucoma earlier by using AI to double-check its own uncertain findings.
medRxiv Apr 23, 2026
Glaucoma surgery in children with primary congenital or juvenile open-angle glaucoma shows persistent vessel narrowing and cup reversal
Rheumatology Cohort
Glaucoma surgery in children with primary congenital or juvenile open-angle glaucoma shows persistent vessel narrowing and cup reversal Study tracks eye blood vessel changes after glaucoma surgery in children
This prospective, comparative cohort study evaluated 24 glaucomatous eyes and 24 age-matched normal control eyes.
Glaucoma surgery in children lowers eye pressure but leaves tiny blood vessels around the optic nerve abnormally narrow even after the opera…
Frontiers Apr 20, 2026
GATT reduces IOP in normal-tension glaucoma patients over 24 months
Rheumatology Cohort
GATT reduces IOP in normal-tension glaucoma patients over 24 months GATT Surgery Lowers Eye Pressure for Years
This single-center retrospective case series evaluated gonioscopy-assisted transluminal trabeculotomy (GATT) in 9 patients with normal-tensi…
GATT surgery lowered eye pressure by an average of 4 mmHg for two years in patients with normal-tension glaucoma, offering a long-term alter…
Frontiers Apr 18, 2026
Rare LOXL1 variants associated with exfoliation syndrome and secondary glaucoma risk in US cohorts
Genetics & Precision Medicine Cohort
Rare LOXL1 variants associated with exfoliation syndrome and secondary glaucoma risk in US cohorts Rare Gene Changes Might Protect Against Glaucoma
This cohort study analyzed exome array and sequence data from 1118 XFS/XFG cases and 3661 controls in the Mass Eye and Ear cohort, plus 284 …
Rare genetic changes in a specific eye gene may protect against glaucoma, offering hope for those with a family history of vision loss.
medRxiv Apr 18, 2026
Phacoemulsification with IOL implantation shows higher IOL prediction error in Chinese PACG patients
Ophthalmology
Phacoemulsification with IOL implantation shows higher IOL prediction error in Chinese PACG patients Why Some Glaucoma Patients Still Need Glasses After Cataract Surgery
An observational study of 165 Chinese primary angle closure glaucoma (PACG) patients and 53 cataract patients found that PACG patients had s…
Eye shape changes after glaucoma surgery can cause blurry vision post-cataract surgery, but new research identifies key measurements to impr…
medRxiv Apr 16, 2026
Modeling study finds variable ciliary body anatomy may affect subliminal cyclophotocoagulation dosing in glaucoma
Ophthalmology
Modeling study finds variable ciliary body anatomy may affect subliminal cyclophotocoagulation dosing in glaucoma Your Glaucoma Laser Treatment Might Be Missing the Target
A modeling study of 24,001 eyes from a biometric database estimated ciliary body arc length (ECBAL) for subliminal transscleral cyclophotoco…
A new eye model reveals that using a one-size-fits-all approach for a common glaucoma laser could be leading to under- or over-treatment for…
medRxiv Apr 11, 2026
Combined cataract and retrobulbar Ahmed drainage surgery shows preliminary IOP reduction in advanced glaucoma
Ophthalmology Cohort
Combined cataract and retrobulbar Ahmed drainage surgery shows preliminary IOP reduction in advanced glaucoma Small study explores combined eye surgery for advanced glaucoma in Black patients
A retrospective cohort of 12 Black and Afro-Latino patients with advanced glaucoma underwent combined phacoemulsification and retrobulbar/in…
A new combined eye surgery lowered pressure and reduced daily drops for advanced glaucoma patients, with stable vision and no serious compli…
Frontiers Apr 9, 2026
Phacoemulsification with endoscopic cyclophotocoagulation lowers IOP and medication needs versus phaco alone in PACG with cataract
Ophthalmology RCT
Phacoemulsification with endoscopic cyclophotocoagulation lowers IOP and medication needs versus phaco alone in PACG with cataract Combined glaucoma and cataract surgery shows modest pressure benefit in small study
This randomized controlled trial enrolled 66 patients with primary angle closure glaucoma and cataract.
Adding a laser treatment to cataract surgery lowered eye pressure and reduced medication needs for patients with a specific type of glaucoma…
Apr 6, 2026
Meta-analysis finds contralateral IOP reduction after unilateral selective laser trabeculoplasty
Ophthalmology Meta-analysis
Meta-analysis finds contralateral IOP reduction after unilateral selective laser trabeculoplasty Unilateral SLT treatment linked to lower pressure in the other eye
A systematic review and meta-analysis of 9 studies (478 eyes) in POAG and OHT patients found unilateral SLT was associated with a mean contr…
Treating one eye with laser therapy lowers pressure in the other eye by an average of 1.85 mmHg without reported safety concerns.
Apr 6, 2026
Microdrop device reduces bottle exhaustion and adverse events in glaucoma patients on monotherapy
Ophthalmology RCT
Microdrop device reduces bottle exhaustion and adverse events in glaucoma patients on monotherapy Small study finds microdrop device may lower eye pressure and reduce medication waste in glaucoma
A prospective randomized crossover trial in 29 adults with stable glaucoma or ocular hypertension on monotherapy found microdrops decreased …
A new device lowers eye pressure better than standard drops and cuts waste, stopping 83% of users from running out of medication early.
Apr 3, 2026